Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - agomelatín - 30 - antidepressiva

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zentiva a.s., slovensko - solifenacín - 73 - spasmolytica

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zentiva a.s., slovensko - solifenacín - 73 - spasmolytica

Slovakiet - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

teva gmbh - fremanezumab - poruchy migrény - calcitonin gene-related peptide (cgrp) antagonists - ajovy je indikovaný na profylaxiu migrény u dospelých, ktorí majú aspoň 4 migréna dní za mesiac.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

h. lundbeck a/s - eptinezumab - poruchy migrény - analgetiká - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

pfizer europe ma eeig  - rimegepant - poruchy migrény - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - poruchy migrény - analgetiká - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glykogénová choroba typu ii - iné alimentárny trakt a metabolizmus výrobky, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).